肝动脉化疗栓塞治疗原发性肝癌的疗效及影响因素

目的观察肝动脉化疗栓塞治疗对原发性肝癌的疗效及影响因素．方法单纯化疗（Ａ组）；化疗加碘油栓塞（Ｂ组）；化疗加碘油加明胶海绵栓塞（Ｃ组）．结果５年内肝动脉化疗栓塞治疗中、晚期肝癌４２８例，３８６例经２个月～５０个月随访．肿瘤缩小率：Ａ组１４％，Ｂ组５５％，Ｃ组７９％（三组间Ｐ＜００１）．肿瘤基本消失：Ｃ组５％，Ａ，Ｂ两组无１例消失．生存时间：１年生存率Ａ组０％，Ｂ组１０％，Ｃ组４５％，其中１２例患者获Ⅱ期手术切除，切除标本病理检查见肿瘤区癌细胞全部或部分凝固坏死，瘤旁癌细胞稀疏．结论影响疗效因素与肿瘤的病理类型及血供情况，门静脉主干瘘和癌栓、肝动脉插管治疗方式有关．     

Clinical experience of hepatic hemangioma undergoing hepatic resection

The indications for surgery on cavernous hemangiomas, the most common benign tumors of the liver, remain unclear. This study reviewed 43 patients with cavernous hemangioma of the liver who underwent hepatic resection from 1984 to 2000. Patients were divided into three groups based on the reasons for surgery. Group I comprised 13 patients whose lesions presented symptoms and dimensions that were the main indications for operation. Group II consisted of 28 patients diagnosed with malignant tumors or who displayed malignant growth that could not be ruled out preoperatively. Group III comprised 2 patients with tumors found incidentally at laparotomy for other malignancies. No surgical mortality related to hepatectomy was noted. Postoperative bile leak was found in 2 (morbidity rate: 4.7%). Patients were followed up from 6 months to 12 years. Thirteen residual tumors progressed in size. The clinical status or symptoms changed only slightly in 10 patients with recurrence. The results suggest that resection therapy is an effective indicator for patients with symptoms and a questionable diagnosis. Hepatic resection may and should be carried out with no mortality and minimal morbidity risks since the lesion is benign.     

Reconstruction of hepatic organoid by hepatic stem cells

Recent advances in culture methods, stem cell research, and tissue engineering provide clues for making tissues in vitro that are functionally and structurally similar to hepatic tissues. To reconstruct hepatic organoids, two approaches to establish the methods have been proposed: the use of cells and the combination of cells and a scaffold (called tissue engineering). Recently, the coculture of hepatic cells (mature hepatocytes, small hepatocytes, hepatoblasts) and hepatic nonparenchymal cells has been reported to form hepatic organoids that possess differentiated hepatic functions. On the other hand, hepatocytes in a roller bottle were shown to form specific structures, consisting of biliary epithelial cells, connective tissue, mature hepatocytes, and endothelial cells. In this review, the studies of hepatic tissue formation in vitro will be summarized.     

Congenital hepatic fibrosis disclosed late by hepatic encephalopathy

A case of hepatic encephalopathy revealing congenital hepatic fibrosis in a 47-year-old woman is reported. The characteristic features of this observation were: a) the long clinical latency of a congenital disease usually discovered in childhood or in adolescence; b) the existence of hepatocellular insufficiency which appeared without any other reason than an ordinary infection; c) the absence of digestive bleeding or portacaval shunt, factors always found in the rare, previously described cases of encephalopathy in congenital hepatic fibrosis.     

肝硬化时肝窦毛细血管化形成机制

目的:探讨肠源性内毒素血症在肝窦毛细血管化形成中的作用及其可能机制.方法:♂ Wistar大鼠40只,完全随机分为模型组(n=32)与正常对照组(n=8),采用复合因素致肝硬化大鼠模型.模型组分别在饲养第2,4,6,8周末,正常对照组在实验开始时,经肠系膜上静脉末端穿刺测PVP.肝脏HE、VG染色,肝脏免疫组织化学染色观察α-SMA、LN、TGF-β1的动态表达,测定外周血中的内毒素、TNF-α、ALT的动态变化,采用扫描电镜观察肝窦内皮细胞失窗孔情况.结果:模型组ALT在第2周末达到高峰(57.84±7.57IU/L),随后逐渐下降;内毒素在第2、4、6周末,各点呈递增趋势,到第8周末时略有下降;TNF-α在第2、4周末呈递增趋势,到第6周末时略有下降,第8周末时又逐渐升高,但各点组均较对照组明显升高(均P<0.05);模型组PVP在第2、4周末,各点呈递增趋势,到第6周末时略有下降,第8周末时又逐渐升高;肝窦内皮细胞扫描电镜结果示随着肝纤维化及硬化程度的加重,窗孔逐渐变小、变少至消失;LN、TGF-β1免疫组织化学染色结果示随着病变的发展,与对照组和同指标前一时间组相比阳性表达逐渐增强(均P<0.05).α-SMA免疫组织化学染色在第2、4、6周末,阳性表达逐渐增强,到第8周末时略有下降.结论:肝硬化大鼠发生了肠源性内毒素血症,其可使TGF-β1、TNF-α、LN等合成增多,促进肝窦内皮细胞去窗孔化,间接参与肝窦毛细血管化的形成.     

肝硬化腹水和肝性胸水的治疗

腹水和肝性胸水是肝硬化失代偿期的并发症,其产生主要是由于门脉压升高、激活交感神经系统、肾素-血管紧张素-醛固酮系统、血浆胶体渗透压降低等因素有关,肝性胸水还有膈肌破裂形成裂孔等有关。治疗上多采用利尿剂、排放腹腔积液、输注白蛋白、腹水浓缩静脉回输、外科手术,甚至肝移植等综合治疗措施。     

Hemodynamic changes in hepatic sinusoids of hepatic steatosis mice

BACKGROUND Fatty liver(FL) is now a worldwide disease. For decades, researchers have been kept trying to elucidate the mechanism of FL at the molecular level, but rarely involve the study of morphology and medical physics. Traditionally, it was believed that hemodynamic changes occur only when fibrosis occurs, but it has been proved that these changes already show in steatosis stage, which may help to reveal the pathogenesis and its progress. Because the pseudolobules are not formed during the steatosis stage, this phenomenon may be caused by the compression of the liver microcirculation and changes in the hemodynamics.AIM To understand the pathogenesis of hepatic steatosis and to study the hemodynamic changes associated with hepatic steatosis.METHODS Eight-week-old male C57 BL/6 mice were divided into three groups randomly(control group, 2-wk group, and 4-wk group), with 16 mice per group. A hepatic steatosis model was established by subcutaneous injection of carbon tetrachloride in mice. After establishing the model, liver tissue from mice was stained with hematoxylin and eosin(HE), and oil red O stains. Blood was collected from the angular vein, and hemorheological parameters were estimated. A two-photon fluorescence microscope was used to examine the flow properties of red blood cells in the hepatic sinusoids.RESULTS Oil red O staining indicated lipid accumulation in the liver after CCl_4 treatment.HE staining indicated narrowing of the hepatic sinusoidal vessels. No significant difference was observed between the 2-wk and 4-wk groups of mice onmorphological examination. Hemorheological tests included whole blood viscosity(mPas, γ = 10 s-1/γ = 100 s-1)(8.83 ± 2.22/4.69 ± 1.16, 7.73 ± 2.46/4.22 ±1.32, and 8.06 ± 2.88/4.22 ± 1.50), red blood cell volume(%)(51.00 ± 4.00, 42.00 ±5.00, and 40.00 ± 3.00), the content of plasma fibrinase(g/L)(3.80 ± 0.50, 2.90 ±0.80, and 2.30 ± 0.70), erythrocyte deformation index(%)(44.49 ± 5.81, 48.00 ±15.29, and 44.36 ± 15.01), erythrocyte electrophoresis rate(mm/s per V/m)(0.55 ±0.11, 0.50 ± 0.11, and 0.60 ± 0.20), revealing pathological changes in plasma components and red blood cells of hepatic steatosis. Assessment of blood flow velocity in the hepatic sinusoids with a laser Doppler flowmeter(mL/min per100 g)(94.43 ± 14.64, 80.00 ± 12.12, and 67.26 ± 5.92) and two-photon laser scanning microscope(μm/s)(325.68 ± 112.66, 213.53 ± 65.33, and 173.26 ± 44.02)revealed that as the modeling time increased, the blood flow velocity in the hepatic sinusoids decreased gradually, and the diameter of the hepatic sinusoids became smaller(μm)(10.28 ± 1.40, 6.84 ± 0.93, and 5.82 ± 0.79).CONCLUSION The inner diameter of the hepatic sinusoids decreases along with the decrease in the blood flow velocity within the sinusoids and the changes in the systemic hemorheology.     

肝星状细胞与肝纤维化研究进展

肝星状细胞(HSC)是肝脏的一种非实质细胞,HSC活化导致细胞外基质(ECM)的增加是肝纤维化形成并最终导致肝硬化、肝功能衰竭的主要原因.因此,加强对HSC激活与凋亡调控机制的研究,有助于我们对肝纤维化发生的本质的认识,从而能更有效地防治肝纤维化.     

Inhibitors of hepatic DNA synthesis in fulminant hepatic failure

In certain etiological groups of patients with fulminant hepatic failure, poor survival may be due to lack of liver regeneration.In vitro experiments have shown that fulminant hepatic failure serum is cytotoxic to rabbit hepatocytes and inhibits DNA synthesis on short-term incubation with isolated regenerating rat hepatocytes. When fulminant hepatic failure serum is injected into partially hepatectomized rats at the time of maximal DNA synthesis, [³H]thymidine incorporation into hepatic DNA is reduced significantly. The effect is greater with sera obtained from patients with fulminant hepatic failure due to non-A, non-B hepatitis or an adverse drug reaction and is associated with a<10,000-dalton fraction. No stimulation of DNA synthesis is observed with injection of the >10,000-dalton serum fraction into normal rats. In preliminary experiments, no increase in epidermal growth factor production has been found in liver failure. Overall, the substances present in fulminant hepatic failure serum appear to be inhibitory rather than stimulatory for liver cell regeneration.Presented at the Proceedings of the International Meeting on Normal and Neoplastic Growth in Hepatology, Bari, Italy, June 1989.     

Prognostic value of hepatic volumetry in fulminant hepatic failure

Serial hepatic volumetry calculated from the liver area on abdominal computed tomography was performed in 19 patients with fulminant hepatic failure to determine a relationship between liver volume and prognosis. All patients received intensified artificial liver support comprised of plasma exchange and hemodiafiltration using high-performance membranes, and 10 patients survived. Liver volume was significantly larger in survivors than in nonsurvivors, both in an initial volumetry performed at the onset of coma and in subsequent volumetry performed 10–20 days after the onset of coma. The difference became more significant in the subsequent volumetry because of the recovery of liver size in some of the survivors and progressive liver shrinkage in all nonsurvivors. All patients with a liver volume greater than 656 ml at 10–20 days after the onset of coma survived, whereas all but one patient with a liver volume less than that died. Multivariate analysis revealed only liver volume in subsequent volumetry had discriminatory power upon prognosis among six prognostic factors. These observations imply that in order to obtain an accurate prediction of fulminant hepatic failure by hepatic volumetry, serial studies at least until 10–20 days after the onset of coma are necessary.     

Anatomo-pathologic study of hepatic toxicity in intra-arterial hepatic chemotherapy

Intra-arterial hepatic chemotherapy is effective in the treatment of colorectal or endocrine carcinomas liver metastasis. However it is potentially toxic for the healthy liver. To check this, we studied non tumoral liver specimens in 14 patients treated by intra-arterial chemotherapy with 5 fluorouracil, 5 fluoro-2 deoxyuridine and an association of 5 fluorouracil and streptozotocin. The main hepatic lesions observed were: sclerosing cholangitis, central vein (dilatation and fibrosis) and moderate hepatocellular necrosis or cholestasis in the centrolobular area. Thus intra-arterial hepatic chemotherapy has important toxic effects on healthy liver, even if clinical and biological liver disturbances are minimal in most cases. Caution must be exercised in using this method.     

Progressive hepatic decompensation with terminal hepatic coma in sarcoidosis

Digestive Diseases and Sciences - In a case of sarcoidosis with portal hypertension, progressive hepatic decompensation terminated in hepatic coma. The difficulties encountered in the diagnosis of...